Location: United States, Massachusetts, Needham
Employees: 51-200
Total raised: $51.2M
Founded date: 1999
Investors 1
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.04.2019 | Series C | $22.5M | - |
| 04.01.2019 | Series B | $28.7M | PBM Capita... |
Mentions in press and media 14
| Date | Title | Description |
| 20.02.2026 | Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch | As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW Investments has stepped in with $100 million to bankroll the launch. The nine-figure fund is conditional on Candel securing F... |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 01.03.2022 | Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank | Additional capital extends cash runway into Q4 of 2023 NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the “Company” or “Candel”), a late clinical stage biopharmaceutical company developing novel... |
| 01.11.2021 | Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies | NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced its participation in upcoming medi... |
| 28.10.2021 | Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer | NEEDHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that data on patient-reported tole... |
| 04.10.2021 | Candel Therapeutics : Announces Participation in Upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting | NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present nove... |
| 01.10.2021 | Candel Therapeutics : Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies | NEEDHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that its President and Chief Execu... |
| 09.09.2021 | Candel Therapeutics : Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021 | Dr. Scott E. Eggener to present safety data from phase 2 clinical trial of CAN-2409 in patients with localized, low to intermediate risk prostate cancer undergoing active surveillance at AdMeTech Foundation’s Fifth Global Summit on Precisio... |
| 03.04.2019 | Term Sheet — Wednesday, April 3: Inside Andreessen’s Big Crypto Play | NEW FUND, NEW STRATEGY Andreessen Horowitz, the 10-year-old venture capital firm, is ready for its next chapter. That chapter includes raising a new growth fund and renouncing its status as a venture firm. Paid Content How can you protect w... |
| 02.04.2019 | Daily funding roundup - April 2nd, 2019 | DynamiCare raised $4.1M; OnScale raised $10M; Fifth Eye Enables landed $11.5M; Perch secured $220M DynamiCare Health: DynamiCare’s platform integrates smart tech, virtual coaching, and traditional testing hardware to guide a person’s recove... |
Show more